Minaris Advances Cell Banking Solutions in Philadelphia for Enhanced Client Support

Minaris Enhances GMP Cell Banking Suites in Philadelphia

In a significant move to bolster its support for cell and gene therapy (CGT) developers, Minaris has announced the enhancement of its GMP cell banking suites at its Philadelphia facility. This initiative aims to integrate comprehensive biosafety testing with cell banking services, streamlining the processes involved in clinical and commercial advancements.

The updated capacities signify Minaris’ commitment to providing cutting-edge GMP infrastructure that adheres to strict regulatory standards. The facility features specialized clean rooms designed to handle multiple concurrent cell banking programs, all while aligning with EU GMP Annex 1 guidelines. The cleanrooms maintain controlled personnel and material flows, ensuring robust cleanroom processes that comply with ISO standards, particularly in the critical zones of ISO 5 (Grade A) within ISO 7 (Grade B) environments.

Dr. Ilya Koltover, President of Minaris Advanced Testing, explained that the enhancements are pivotal as cell banking is among the most critical steps in the development of biologics and advanced therapies. Clients often seek partners that can guarantee quality, reliability, and regulatory adherence from the beginning, which is the very essence of this enhancement.

The new suites not only modernize the operational aspects but also introduce improved environmental monitoring and stringent quality controls, effectively enhancing contamination management. Thanks to established tech transfer processes, programs can transition seamlessly from development to commercial supply.

Dr. Orla Cloak, Chief Executive Officer of Minaris, emphasized that operational rigor is essential within their GMP environments. The upgrades improve efficiency while ensuring top-notch standards are met for all GMP production activities. Additionally, integrated characterization and regular visibility into manufacturing processes allow clients to make informed decisions and progress towards regulatory-ready cell banks.

This enhancement reflects Minaris Advanced Testing's integrated operational model, merging GMP cell banking with regulatory-focused characterization and biosafety testing in a centralized U.S. hub. The diverse capabilities, including sterility testing, mycoplasma detection, viral safety assessments, and identity testing, facilitate the management of both Master and Working Cell Banks, providing clients with timely data and coordinated oversight of their projects.

Centralizing both banking and testing functions in Philadelphia simplifies the process for developers by synchronizing manufacturing and quality project management. Clients benefit from dedicated support, transparent communication, and daily updates on manufacturing status, which aids in tracking progress and planning subsequent steps.

Minaris Advanced Testing is committed to its Philadelphia site as a vital hub for cell banking and testing, synergizing state-of-the-art GMP facilities with an extensive knowledge base acquired over decades. This holistic approach minimizes risks, optimizes program timelines, and better prepares developers for pivotal clinical and commercial manufacturing milestones.

With over 25 years of experience in CGT and a legacy of more than 40 years in biosafety testing, Minaris combines deep-rooted expertise with advanced methodologies tailored for the evolving therapeutic landscape. The company envisions its Philadelphia facility as a critical nexus for supporting innovators in their journey from Investigational New Drug application through to commercial supply, delivering a range of services from biosafety testing to product characterization.

Through its dual divisions, Minaris Advanced Therapies and Minaris Advanced Testing, the organization fosters innovation alongside its partners, exemplifying a client-first commitment that distinguishes Minaris. This update is not just an operational enhancement but a reaffirmation of the organization’s dedication to advancing therapeutic options and improving patient outcomes on a global scale.

For more information on Minaris and their services, visit minaris.com or reach out via LinkedIn.